Trumps HHS Nominee Got A Sweetheart Deal From Foreign Biotech Firm
Source: TalkingpointMemo
When tiny Australian biotech firm Innate Immunotherapeutics needed to raise money last summer, it didnt issue stock on the open market. Instead, it offered a sweetheart deal to sophisticated U.S. investors, company documents show.
It sold nearly $1 million in discounted shares to two American congressmen sitting on House committees with the potential power to advance the companys interests, according to company records and congressional filings. They paid 18 cents a share for a stake in a company that was rapidly escalating in value, rising to more than 90 cents as the company promoted an aggressive plan to sell to a major pharmaceutical company. Analysts said the stock price could go to $2.
One of the beneficiaries was Rep. Tom Price, a Georgia Republican poised to become secretary of the Department of Health and Human Services, which regulates pharmaceuticals. Price told HHS ethics officials Thursday that if appointed, he will divest himself of the Australian stock as well as stock in about 40 other companies that could pose conflicts. He said he would sell within 90 days of appointment and abstain from any decision-making about companies in which he or his family has had an interest.
He has already seen about a 400 percent paper gain in his investment in Innate Immuno, stock trading records show.
Read more: http://talkingpointsmemo.com/news/kaiser-health-news-tom-price-hhs-nominee-deal
WOW
WHO'd a thunk it ?????